Skip to content
To the full analysis

Jiangsu Hengrui Medicine stock: balance sheet and debt

600276.SS
$7.19Closing price of 12 Nov 2026MEQIRI Score 69 out of 100

Jiangsu Hengrui Medicine has a debt to equity ratio of 0.02 and an interest coverage of over 100x.

Daily figure as of 13 Nov 2026

Debt / Equity
0.02
Interest coverage
> 100x
Current ratio
8.08
Cash & equivalents
$6.16B
Total assets
$10.48B
Equity ratio
88.4%
Goodwill and intangible assets
$1.02B
not split out
Net debt
−$6.02B
More cash than debt

Total assets and equity ratio

How large the balance sheet of Jiangsu Hengrui Medicine Co., Ltd. is, how much of it is equity and how much is goodwill from acquisitions.

Equity ratio

Figures as a table
YearTotal assetsGoodwill and intangible assetsof which goodwillEquity ratioNet debt
2006$218.64M$4.3Mnot split out86.2%−$79.26M
2007$301.98M$4.49Mnot split out81.1%−$117.48M
2008$338.07M$4.38Mnot split out89.8%−$69.77M
2009$449.72M$7.54Mnot split out88.9%−$104.56M
2010$584.21M$7.85Mnot split out89.2%−$146.22M
2011$722.53M$7.7Mnot split out90.9%−$139.38M
2012$883.67M$10.03Mnot split out92.4%−$197.87M
2013$1.08B$30.39Mnot split out92.2%−$322.29M
2014$1.36B$29.97Mnot split out91.2%−$515.73M
2015$1.72B$29.37Mnot split out90.1%−$768.28M
2016$2.15B$42.7Mnot split out89.8%−$730.13M
2017$2.71B$41.88Mnot split out88.4%−$560.66M
2018$3.35B$40.89Mnot split out88.5%−$485.11M
2019$4.13B$52.45Mnot split out90.5%−$1.97B
2020$5.21B$51.18Mnot split out88.6%−$2.22B
2021$5.89B$105.34Mnot split out90.6%−$2.78B
2022$6.35B$330.06Mnot split out90.7%−$2.48B
2023$6.57B$506.33Mnot split out93.7%−$3.11B
2024$7.52B$754.3Mnot split out91.9%−$3.75B
2025$10.48B$1.02Bnot split out88.4%−$6.02B

The equity ratio divides total equity, including non-controlling interests, by total assets. Net debt is debt minus cash and short-term investments; a negative figure means cash exceeds debt. In years without separate goodwill, the table shows the sum of goodwill and intangible assets, because the data do not list goodwill separately there.

Equity and debt

What the company owns and owes

  • Cash & equivalents
  • Equity
  • Debt
Figures as a table
YearCash & equivalentsEquityDebtDebt / Equity
2006$86.46M$186.78M$7.2M0.04
2007$126.48M$242.3M$9M0.04
2008$69.77M$299.08M$00
2009$106.06M$391.07M$1.5M0
2010$149.22M$507.98M$3M0.01
2011$142.37M$633.48M$3M0
2012$199.37M$781.93M$1.5M0
2013$325.29M$953.36M$3M0
2014$517.23M$1.19B$1.5M0
2015$769.78M$1.49B$1.5M0
2016$736.65M$1.86B$6.51M0
2017$639.91M$2.3B$79.25M0.03
2018$583.32M$2.96B$98.21M0.03
2019$2.03B$3.72B$62.96M0.02
2020$2.46B$4.57B$240.18M0.05
2021$2.81B$5.25B$22.73M0
2022$2.68B$5.67B$203.92M0.04
2023$3.13B$6.07B$11.27M0
2024$3.76B$6.83B$10.35M0
2025$6.16B$9.19B$140.66M0.02

Data status and sources

Score
Daily value of 13 Nov 2026, recalculated nightly
Price
Closing price of 12 Nov 2026
Latest annual report
Fiscal year 2025, period end 31 Dec 2025
Currency
Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = CN¥6.6683)
Source
Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.

Mandatory disclosures for this rating

  • ; time horizon around 12 months
  • Rated Neutral since 13 Nov 2026, previously Strong
  • Valuation signal Undervalued since 11 Nov 2026, previously Fairly valued
  • End-of-day prices, metrics cached for up to 24 hours
  • Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
  • Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
  • Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.

MEQIRI counts visits without cookies. With your consent we remember for 90 days where you came from, also in your account, count page changes and time on page, recognise your next visit and load the Meta Pixel, which measures our advertising. You can withdraw your consent at any time under Cookie settings. Privacy